

0220 7300 #

Box 509



Attorney's Docket No.: US 1257/01 (VA)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : November 28, 2001  
Theresa H. SMITH, Ph.D. :  
Serial No.: 09/931,009 :  
Filed: August 17, 2001 :  
For: PRO-INFLAMMATORY : Initial Patent  
FIBRINOPEPTIDE : Examination Division

**RESPONSE**  
**TO**  
**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS**  
**CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE**  
**DISCLOSURES**

Honorable Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

Responsive to the Notice to Comply With Requirements For Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated  
October 23, 2001, attached hereto are the following:

1. A substitute paper copy of the Sequence Listing;

**S.N. 09/931,009**

2. A replacement diskette (2 copies) containing the substitute Sequence Listing; and
3. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

It is submitted that the substitute paper copy, and the replacement diskette, containing the Sequence Listing, include no new matter. Further, it is submitted that the amendments to the Sequence Listing were formal in nature and are fully supported by the application, as filed. These amendments are being made to overcome the errors noted in the Raw Sequence Error Report attached to the Notice.

Finally, it is submitted that the content of the Sequence Listing information recorded on the replacement diskette (2 copies) is identical to the substitute copy of the Sequence Listing provided herewith.

It is believed that no fee is due for this submission. Should that determination be incorrect, however, the Examiner is hereby authorized to charge any deficiencies, or credit any overpayment, to our Deposit Account No. 01-0433, and notify the undersigned in due course.

**S.N. 09/931,009**

Should the Examiner have any questions or wish to discuss further this matter,  
please contact the undersigned at the telephone number provided below.

Respectfully Submitted,

A handwritten signature in black ink, appearing to read 'DAGAR', is written over a horizontal line.

DINESH AGARWAL  
Attorney for Applicant(s)  
Reg. No. 31,809

Law Office - Dinesh Agarwal, P.C.  
5350 Shawnee Road, Suite 330  
Alexandria, Virginia 22312  
Telephone: (703) 642-9400  
Fax: (703) 642-9402  
DA/mm




## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov


APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/931,009	10/18/2001	Theresa H. Smith	US 1257/01 (VA)

Law Office - Dinesh Agarwal, P.C.  
Suite 330  
5350 Shawnee Road  
Alexandria, VA 22312



CONFIRMATION NO. 2825

## FORMALITIES LETTER



Date Mailed: 10/23/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

*HA*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE